

UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE PATENT TRIAL AND APPEAL BOARD

1 MYLAN PHARMACEUTICALS INC. *
 2 and AMNEAL PHARMACEUTICALS *
 3 LLC, *
 4 * Case No. IPR2015-00643
 5 Petitioners, * (8,232,250 B2)
 6 *
 7 VS. * Case No. IPR2015-00644
 8 * (8,399,413 B2)
 9 *
 10 YEDA RESEARCH AND *
 11 DEVELOPMENT CO. LTD., * Case No. IPR2015-00830
 12 * (8,969,302 B2)
 13 Patent Owner. *

ORAL AND VIDEOTAPED DEPOSITION OF
EDWARD J. FOX, MD
JANUARY 26, 2016

ORAL AND VIDEOTAPED DEPOSITION OF EDWARD
J. FOX, MD, produced as a witness at the instance of
the Petitioner Mylan Pharmaceuticals Inc. and duly
sworn, was taken in the above-styled and numbered cause
on the 26th day of January, 2016, from 9:22 a.m. to
4:30 p.m., before Marsha Yarberry, Certified Shorthand
Reporter in and for the State of Texas, reported by
machine shorthand, at the offices of Wilson Sonsini
Goodrich & Rosati, 900 South Capital of Texas Highway,
Las Cimas IV, 5th Floor, Austin, Texas.

Veritext Legal Solutions

215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830

APPEARANCES

FOR THE PETITIONER MYLAN PHARMACEUTICALS INC.:

MR. DAVID L. ANSTAETT
Perkins Coie
One East Main Street, Suite 201
Madison, Wisconsin 53703-5118
608-663-5408
DAnstaett@perkinscoie.com

--and--

MS. COURTNEY M. PROCHNOW
Perkins Coie
1888 Century Park East, Suite 1700
Los Angeles, California 90067-1721
310-788-3284
CProchnow@perkinscoie.com

--and--

MS. SHANNON BLOODWORTH (Via Telephone)
MR. ROBERT SWANSON (Via Telephone)
Perkins Coie
700 13th Street, NW, Suite 600
Washington, DC 20005-3960
202-654-6200

--and--

MS. LORELEI P. WESTIN
Wilson Sonsini Goodrich & Rosati
12235 El Camino Real, Suite 200
San Diego, California 92130
858-350-2300
lwestin@wsgr.com

Veritext Legal Solutions
Mid-Atlantic Region
1250 Eye Street NW - Suite 1201
Washington, D.C. 20005

Veritext Legal Solutions

215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830

APPEARANCES (cont'd)

FOR THE PETITIONER AMNEAL PHARMACEUTICALS LLC:

MR. VINCENT L. CAPUANO
Duane Morris LLP
100 High Street, Suite 2400
Boston, Massachusetts 02110-1724
857-488-4250
vcapuano@duanemorris.com

FOR THE PATENT OWNER:

MR. JOHN T. BENNETT
Goodwin Procter
Exchange Place
Boston, Massachusetts 02109
617-570-1000
jbenett@goodwinprocter.com

--and--
MR. ANDREW E. RILEY
Goodwin Procter
The New York Times Building
620 8th Avenue
New York, New York 10018-1405
212-813-8800
ariley@goodwinprocter.com

ALSO PRESENT:

Mr. Matthew Greinert, Mylan in-house counsel
Ms. Lori Wolfe, Teva in-house counsel
Mr. Jason Lemley, Videographer

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

INDEX

PAGE

Appearances.....	2
EDWARD J. FOX, MD	
Examination by Mr. Anstaett.....	7
Examination by Mr. Bennett.....	211
Further Examination by Mr. Anstaett.....	213
Changes and Corrections.....	215
Signature.....	216
Reporter's Certificate.....	217

EXHIBITS

NO. DESCRIPTION	PAGE/LINE REFERENCED
Exhibit 1005.....	192/15
PCT application	
Exhibit 1006.....	131/8
Article titled Randomized, Double-Blind, Dose-Comparison Study of Glatiramer Acetate in Relapsing-Remitting MS	
Exhibit 1008.....	43/13
Article titled Copolymer 1 (Glatiramer Acetate) in Relapsing Forms of Multiple Sclerosis: Open Multicenter Study of Alternate-Day Administration	
Exhibit 1010.....	27/1
Study by Dr. Omar Khan	
Exhibit 1011.....	41/25
Study comparing daily injections of 20 milligrams of glatiramer acetate with every-other-day 20-milligram glatiramer acetate injections	

EXHIBITS (cont'd)

NO.	DESCRIPTION	PAGE/LINE REFERENCED
1		
2		
3		
4	Exhibit 1067.....	9/10
5	Petitioners' Notice of Deposition of	
6	Dr. Edward J. Fox	
7	Exhibit 1068.....	86/14
8	Abstract	
9	Exhibit 1069.....	102/4
10	Abstract	
11	Exhibit 1070.....	123/22
12	Article titled Glatiramer Acetate:	
13	Successful Desensitization For Treatment of	
14	Multiple Sclerosis	
15	Exhibit 1071.....	151/6
16	Article titled Gray Matter Atrophy in	
17	Multiple Sclerosis: A Longitudinal Study	
18	Exhibit 1072.....	161/3
19	Fourth Declaration of Edward J. Fox, M.D.,	
20	PH.D.	
21	Exhibit 1073.....	181/2
22	Article titled Tolerability and Safety of	
23	Novel Half Milliliter Formulation of	
24	Glatiramer Acetate For Subcutaneous	
25	Injection: An Open-Label Multicenter,	
	Randomized Comparative Study	
	Exhibit 1074.....	203/11
	Article titled Exorbitant Drug Costs May	
	Price Out Patients	
	Exhibit 2028.....	135/10
	Slide presentation	

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.